PDPN and atherosclerosis: Podoplanin’s role as a marker of lymphoangiogenesis, inflammation, and platelet activation [43] suggests that reduced PDPN levels in patients with angiographically confirmed atherosclerosis may reflect endothelial dysfunction and impaired vascular remodeling, including lymphoangiogenesis.